KMT2A and lymphoma: In terms of accuracy, the proposed BIMSSA (Boruta + IMRMR + SSA) achieved 96.7% for ALL-AML, 96.2% for Lymphoma, 95.1% for MLL, and 97.1% for the SRBCT cancer datasets, according to the empirical evaluations.